
|Videos|March 7, 2023
A Molecular Pathologist’s Insight into Institutional Best Practices for NSCLC Biomarker Testing
Dr Vail shares insight into his ideal institutional approach to biomarker testing for NSCLC, emphasizing the need for local molecular pathology expertise and available in-house biomarker panels.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
3
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
4
New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches
5



















